2023 Fiscal Year Final Research Report
Novel therapy using human iPS cell-derived endocrine cell
Project/Area Number |
21K08292
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 53040:Nephrology-related
|
Research Institution | Kansai Medical University |
Principal Investigator |
|
Project Period (FY) |
2021-04-01 – 2024-03-31
|
Keywords | 再生医学 / iPS細胞 / 移植・再生医療 / エリスロポエチン / 副甲状腺 / 細胞療法 / 腎性貧血 / CKD-MBD |
Outline of Final Research Achievements |
Endocrine cells, such as erythropoietin-producing cells and parathyroid cells, were generated from human iPS cells. The differentiation induction method was improved to induce endocrine cells with high efficiency. We generated iPS cells expressing markers of the produced endocrine hormones and applied for a patent. These cells were transplanted into originally developed endocrine-deficient mouse models, and endocrine hormone production was detected in vitro to elucidate the pathophysiology of the disease. There are a number of patients in need of endocrine replacement therapy, and human iPS cell-derived endocrine cells can provide completely novel cellular therapies and drug development. The research results are not only useful for future basic research but also very promising for the development of endocrine hormone replacement therapy and new drugs.
|
Free Research Field |
再生医学 腎臓内科学 内分泌学
|
Academic Significance and Societal Importance of the Research Achievements |
ヒトiPS細胞を用いた再生医療の試みがなされているが、エリスロポエチン産生細胞や副甲状腺に関しては報告がほとんど存在せず、本研究は全く新規で独自のものである。本研究成果は、内分泌疾患治療に対する安価でより生理的な管理を可能とする医療技術の向上に加え、新規治療法の開発による本邦の医薬産業界の活性化をもたらすものである。患者自身の体細胞から樹立され、ほぼ無限に増殖する能力を有する多能性幹細胞であるiPS細胞を用いることで、免疫抑制の必要ない内分泌細胞を大量に作製することも可能であり、今後も需要の増す内分泌疾患治療に対して有効な手段になりうる。
|